| Literature DB >> 28592842 |
Chang-Chyi Jenq1,2, Cheng-Chieh Hung1,2, Kuo-Chang Juan3, Kuang-Hung Hsu4,5,6.
Abstract
Aggressively applying e-interventions in the health care industry has become a global trend to improve the quality of medical care. The present retrospective study evaluated the effect of electronic information systems on the quality of medical care provide to hemodialysis (HD) patients. In total, 600 patients (300 patients each in the e-intervention and non-e-intervention groups, were matched for sex, age, HD duration, diabetes, and hypertension) receiving HD at the study institute for four years were included in this study. The e-intervention group had significantly fewer hospitalization days than the non-e-intervention group. Cox regression analysis demonstrated that the non-e-intervention group had a significantly higher mortality rate than the e-intervention group. Stratified analysis revealed significant differences between the e-intervention and non-e-intervention groups in their serum albumin levels, urea reduction ratios, and cardiothoracic ratios at 1-year follow-up. The patients in the e-intervention group had a significantly higher HD blood flow rate, fewer hospitalization days and a lower 4-year all-cause mortality rate than those in the non-e-intervention group. The implementation of the e-intervention improved patient outcomes, but additional studies are required to evaluate the cost effectiveness of such implementations.Entities:
Mesh:
Year: 2017 PMID: 28592842 PMCID: PMC5462823 DOI: 10.1038/s41598-017-02815-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic factors and clinical characteristics of the study patients.
| Variables | All (n = 600) Frequency (%)/Mean ± SD | Non-e group (n = 300) Frequency (%)/Mean ± SD | e group (n =300) Frequency (%)/Mean ± SD | p value |
|---|---|---|---|---|
|
| ||||
|
| 58.96 ± 11 | 59.04 ± 11.15 | 58.88 ± 10.86 | 0.8641 |
|
| ||||
| Male | 312 (52.00) | 156 (52.00) | 156 (52.00) | 1.0000 |
| Female | 288 (48.00) | 144 (48.00) | 144 (48.00) | |
|
| ||||
| Under junior high school | 419 (69.83) | 197 (65.67) | 222 (74.00) | 0.0328 |
| Senior high school and above | 181 (30.17) | 103 (34.33) | 78 (26.00) | |
|
| ||||
| Laborer | 65 (10.83) | 34 (11.3) | 31 (10.3) | 0.9245 |
| Non-laborer | 111 (18.50) | 55 (18.3) | 56 (18.7) | |
| Unemployed | 424 (70.67) | 211 (70.3) | 213 (71.0) | |
|
| ||||
| Married | 334 (55.67) | 118 (39.33) | 216 (72.00) | <0.0001 |
|
| 22.56 ± 3.4 | 22.4 ± 3.55 | 22.86 ± 3.1 | 0.1808 |
|
| ||||
|
| 7.19 ± 5.29 | 7.16 ± 5.31 | 7.22 ± 5.28 | 0.9019 |
|
| ||||
| CGN | 258 (43.00) | 149 (49.67) | 109 (36.33) | <0.0001 |
| Diabetes mellitus | 123 (20.50) | 60 (20.00) | 63 (21.00) | |
| Hypertension | 155 (25.83) | 42 (14.00) | 113 (37.67) | |
| Others | 64 (10.67) | 15 (16.33) | 15 (5.00) | |
|
| ||||
|
| ||||
| Positive | 71 (11.83) | 20 (6.67) | 51 (17.00) | <0.0001 |
|
| ||||
| Positive | 96 (16.00) | 51 (17.00) | 45 (15.00) | 0.5039 |
|
| ||||
| Yes | 120 (20.00) | 60 (20.00) | 60 (20.00) | 1.0000 |
|
| ||||
| Yes | 202 (33.67) | 101 (33.67) | 101 (33.67) | 1.0000 |
|
| ||||
| A-V fistula | 454 (75.67) | 225 (75.00) | 229 (76.33) | 0.4248 |
| A-V graft | 121 (20.17) | 65 (21.67) | 56 (18.67) | |
| Double lumen catheter^ | 25 (4.17) | 10 (3.33) | 15 (5.00) | |
|
| ||||
| Yes | 542 (90.33) | 260 (86.67) | 282 (94.00) | 0.0021 |
| Surface area of the dialyzer (m2) | 1.96 ± 0.29 | 1.98 ± 0.28 | 1.94 ± 0.3 | 0.1484 |
| Blood flow (mL/min) | 288.18 ± 40.04 | 285.67 ± 36.91 | 290.7 ± 42.86 | 0.1238 |
| Albumin (g/dL) | 3.95 ± 0.34 | 3.93 ± 0.34 | 3.97 ± 0.34 | 0.1892 |
| Pre-HD creatinine (mg/dL) | 10.64 ± 2.34 | 10.54 ± 2.35 | 10.74 ± 2.33 | 0.3254 |
| nPCR (g/kg/day) | 1.26 ± 0.38 | 1.25 ± 0.37 | 1.26 ± 0.39 | 0.9166 |
| TACurea (mg/dL) | 41.55 ± 10.92 | 41.21 ± 10.95 | 41.86 ± 10.9 | 0.4758 |
| Potassium (meq/L) | 4.92 ± 0.72 | 4.97 ± 0.71 | 4.88 ± 0.72 | 0.1469 |
| Kt/V | 1.79 ± 0.32 | 1.79 ± 0.35 | 1.8 ± 0.29 | 0.6175 |
| URR | 0.77 ± 0.06 | 0.77 ± 0.06 | 0.76 ± 0.07 | 0.1877 |
| Hematocrit (Hct, %) | 31.86 ± 4.09 | 32.2 ± 4.1 | 31.52 ±4.06 | 0.0436 |
| Iron administration by vein | ||||
| Yes | 124 (20.67) | 42 (14.00) | 82 (27.33) | <0.0001 |
| Monthly EPO usage (1000U/month)* | 16 (8, 22) | 16 (8, 22) | 18 (11, 22) | 0.0090 |
| Calcium (mg/dL) | 9.67 ± 0.94 | 9.64 ± 0.93 | 9.71 ± 0.95 | 0.4001 |
| Phosphate (mg/dL) | 4.71 ± 1.37 | 4.63 ± 1.33 | 4.79 ± 1.41 | 0.1679 |
| iPTH (ng/mL)* | 134.15 | 138.3 | 127.3 | 0.6062 |
| (49.9, 312.15) | (49.9, 324.2) | (50, 288.3) | ||
| Total cholesterol (mg/dL) | 174.9 ± 37.59 | 172.3 ± 36.94 | 177.39 ± 38.1 | 0.1064 |
| Glucose (mg/dL)* | 97 (85, 132) | 99.5 (87,133.5) | 95 (82, 129) | 0.0277 |
| Cardiothoracic ratio | 0.49 ± 0.06 | 0.5 ± 0.07 | 0.48 ± 0.06 | <0.0001 |
|
| ||||
| Total length of hospitalization (days/person-year) | 1.63 ± 8.99 | 3.26 ± 12.51 | 0 ± 0 | <0.0001 |
|
| ||||
| Deaths | 105 (17.50) | 59 (19.67) | 46 (15.33) | 0.1620 |
| Survivors | 495 (82.50) | 241 (80.33) | 254 (84.67) | |
| Cause of death n (%) | ||||
| Gastro-entero-intestine (GI) | 14 (10.37) | 8 (10.81) | 6 (9.84) | 0.5890 |
| Cardiovascular Diseases (CVDs) | 37 (27.41) | 18 (24.32) | 19 (31.15) | |
| Infections | 76 (56.30) | 42 (56.76) | 34 (55.74) | |
| Others (including injuries, lung diseases, etc) | 8 (5.93) | 6 (8.11) | 2 (3.28) | |
e group: e-intervention group; non-e group: non-e-intervention group; HD: hemodialysis; CGN: chronic glomerulonephritis; HBV: hepatitis B virus; HCV: hepatitis C virus; A-V: arteriovenous; nPCR: normalized protein catabolic rate; TACurea: time-averaged concentration of urea; URR: urea reduction ratio; EPO: erythropoietin; iPTH: intact parathyroid hormone.
^ Double lumen catheter includes tunneled cuffed catheter
*The variables with skew distribution were presented as median (1st-quartile, 3rd-quartile) and tested with Mann-Whitney U-test accordingly.
Factors associated with 4-year all-cause mortality of the hemodialysis patients.
| Variables | Person-months | Number of death | Univariate measure | Multivariate-adjusted measure | ||
|---|---|---|---|---|---|---|
| HR | 95%CI | HR | 95%CI | |||
|
| ||||||
| Non-e-intervention | 12880.8 | 65 | 1.264 | (0.881, 1.813) | 1.991* | (1.194, 3.317) |
| e-intervention | 13442.5 | 54 | — | — | — | — |
|
| ||||||
|
| ||||||
| Under junior high school | 17977.5 | 104 | 3.267* | (1.901, 5.615) | 1.913* | (1.012, 3.616) |
| Senior high school and above | 8345.8 | 15 | — | — | — | — |
|
| ||||||
| Laborer | 3076.0 | 4 | — | — | ||
| Non-laborer | 5070.4 | 16 | 2.438 | (0.815, 7.293) | ||
| Unemployment | 18177.0 | 99 | 4.274* | (1.573, 11.613) | ||
|
| ||||||
| Married | 13706.1 | 16 | — | — | — | — |
| Not married | 12617.2 | 103 | 6.125* | (3.616,10.375) | 5.500* | (2.934, 10.311) |
|
| — | — | 0.981 | (0.926, 1.039) | ||
|
| ||||||
|
| — | — | 0.973 | (0.939, 1.009) | ||
|
| ||||||
|
| ||||||
| Negative | 23076.8 | 109 | — | — | — | — |
| Positive | 3246.4 | 10 | 0.647 | (0.339, 1.237) | 1.246 | (0.598, 2.598) |
|
| ||||||
| Negative | 22017.7 | 97 | — | — | ||
| Positive | 4305.5 | 22 | 1.153 | (0.726, 1.832) | ||
|
| ||||||
| No | 21570.8 | 70 | — | — | ||
| Yes | 4752.5 | 49 | 3.271* | (2.269, 4.715) | ||
|
| ||||||
| No | 17324.5 | 81 | — | — | ||
| Yes | 8998.8 | 38 | 0.900 | (0.612, 1.324) | ||
|
| ||||||
| A-V fistula | 20119.3 | 75 | — | — | — | — |
| A-V graft | 5252.0 | 31 | 1.596* | (1.050, 2.425) | 1.589 | (0.953, 2.649) |
| Double lumen catheter | 952.0 | 13 | 3.822* | (2.119, 6.894) | 1.975 | (0.952, 4.095) |
|
| ||||||
| Daily urine amount (mL/day) | — | — | 0.970* | (0.949, 0.992) | ||
| Surface area of the dialyzer (m2) | — | — | 1.316 | (0.695, 2.491) | ||
| Albumin (g/dL) | — | — | 0.249* | (0.150, 0.414) | 0.771 | (0.356, 1.669) |
| Pre-HD creatinine (mg/dL) | — | — | 0.748* | (0.686, 0.815) | 0.813* | (0.708, 0.933) |
| nPCR (g/kg/day) | — | — | 0.452* | (0.257, 0.794) | ||
| TACurea (mg/dL) | — | — | 0.963* | (0.946, 0.981) | ||
| Potassium (meq/L) | — | — | 0.647* | (0.497, 0.843) | ||
| Kt/V | — | — | 0.881 | (0.499, 1.555) | ||
| URR | — | — | 2.572 | (0.153, 43.341) | 4.251 | (0.132, 136.648) |
| Hematocrit (%) | — | — | 0.963 | (0.920, 1.008) | 1.034 | (0.956, 1.117) |
| Iron supply | ||||||
| No | 20830.5 | 91 | — | — | — | — |
| Yes | 5492.8 | 28 | 1.166 | (0.763, 1.781) | 1.274 | (0.780, 2.081) |
| Monthly EPO usage (1000U/month) | — | — | 1.016 | (0.995, 1.037) | 1.010 | (0.981, 1.041) |
| Calcium (mg/dL) | — | — | 0.856 | (0.701, 1.047) | ||
| Phosphate (mg/dL) | — | — | 0.836* | (0.727, 0.961) | 1.107 | (0.918, 1.334) |
| iPTH (ng/mL) | — | — | 0.999 | (0.999, 1.000) | ||
| Total cholesterol (mg/dL) | — | — | 0.991* | (0.985, 0.996) | 0.994 | (0.987, 1) |
| Cardiothoracic ratio | — | — | 555.934* | (41.821, 7390.177) | 28.888 | (0.818, 1020.780) |
| Glucose (mg/dL) | — | — | 1.004* | (1.003, 1.006) | 1.003* | (1.001, 1.005) |
| Blood flow (cc/min) | — | — | 0.989* | (0.984, 0.993) | 1.002 | (0.994, 1.009) |
| Anuria | ||||||
| No | 2778.5 | 1 | — | — | — | — |
| Yes | 23544.8 | 118 | 14.197* | (1.984, 101.596) | 6.031 | (0.809, 44.966) |
| Hospitalization days | — | — | 1.017* | (1.007, 1.027) | ||
|
| ||||||
| GI | 11686.3 | 35 | 1.818 | (0.944, 3.503) | ||
| CVDs | 4896.5 | 49 | 6.262* | (3.329, 11.779) | ||
| Infections | 7235.4 | 12 | 5.772* | (2.871, 11.602) | ||
| Others | 2505.1 | 23 | — | — | ||
HD: hemodialysis; A-V: arteriovenous; EPO: erythropoietin; iPTH: intact parathyroid hormone; URR: urea reduction ratio; HBV: hepatitis B virus; HCV: hepatitis C virus; nPCR: normalized protein catabolic rate; TACurea: time-averaged concentration of urea
*p-value < 0.05 in the univariate and multivariate-adjusted analyses.
Clinical characteristics and outcomes associated factors of the study patients one year after the e-intervention.
| Variables | All (n = 600) | Non-e group (n = 300) | e group (n = 300) | p- value^ | |||
|---|---|---|---|---|---|---|---|
| Frequency(%)/Mean ± SD | Frequency(%)/Mean ± SD | Frequency(%)/Mean ± SD | |||||
|
| |||||||
|
| 1.66 | ±9.08 | 3.39 | ±12.77 | 0.00 | ±0.00 | <0.0001 |
|
| 287.39 | ±39.31 | 283.52 | ±35.97 | 291.08 | ±41.99 | 0.0032 |
|
| |||||||
| Deaths | 13 (2.17) | 13 (4.33) | 0 (0.0) | <0.0001 | |||
| Survivors | 909 (97.5) | 287 (95.67) | 300 (100.0) | ||||
|
| |||||||
| Albumin (g/dL) | 3.94 | ±0.33 | 3.9 | ±0.34 | 3.97 | ±0.32 | 0.0041 |
| Pre-HD creatinine (mg/dL) | 10.76 | ±2.48 | 10.73 | ±2.54 | 10.78 | ±2.44 | 0.733 |
| nPCR (g/kg/day) | 1.28 | ±0.43 | 1.28 | ±0.43 | 1.28 | ±0.44 | 0.8284 |
| TACurea (mg/dL) | 41.87 | ±11.54 | 42.2 | ±12.3 | 41.55 | ±10.79 | 0.569 |
| Potassium (meq/L) | 4.93 | ±0.76 | 4.93 | ±0.77 | 4.94 | ±0.75 | 0.7899 |
| Kt/V | 1.51 | ±0.35 | 1.51 | ±0.42 | 1.5 | ±0.26 | 0.9566 |
| URR | 0.77 | ±0.06 | 0.76 | ±0.06 | 0.78 | ±0.06 | <0.0001 |
| Hematocrit (%) | 31.88 | ±4.1 | 32.05 | ±4.26 | 31.72 | ±3.94 | 0.6287 |
| Iron administration by vein | |||||||
| No | 463 (78.88) | 236 (82.23) | 227 (75.67) | 0.0509 | |||
| Yes | 124 (21.12) | 51 (17.77) | 73 (24.33) | ||||
| Monthly EPO usage (1000U/month)* | 16 (10,22) | 16 (8,20) | 16 (12, 22) | 0.0979 | |||
| Calcium (mg/dL) | 9.76 | ±0.99 | 9.82 | ±1.01 | 9.71 | ±0.96 | 0.2305 |
| Phosphate (mg/dL) | 4.9 | ±1.49 | 4.89 | ±1.57 | 4.91 | ±1.42 | 0.8149 |
| iPTH (ng/mL)* | 181.5 (62.1, 455.2) | 178.2 (53.4, 441.5) | 188.1 (71.7, 478.25) | 0.6106 | |||
| Total cholesterol (mg/dL) | 169.69 | ±36.21 | 168.94 | ±35.75 | 170.37 | ±36.66 | 0.6157 |
| Glucose (mg/dL)* | 96.0 (84.0, 128.0) | 97 (85, 129) | 94 (82, 127) | 0.2219 | |||
| Cardiothoracic ratio | 0.49 | ±0.06 | 0.50 | ±0.07 | 0.48 | ±0.06 | <0.0001 |
e group: e-intervention group; non-e group: non-e-intervention group; HD: hemodialysis; nPCR: normalized protein catabolic rate; TACurea: time-averaged concentration of urea; URR: urea reduction ratio; EPO: erythropoietin; iPTH: intact parathyroid hormone.
*The variables with skew distribution were presented as median (1st-quartile, 3rd-quartile) and tested with Mann–Whitney U-test accordingly.
^The p-value was calculated by multiple regression models while adjusted by age, gender, and HD duration.
Figure 1Survival functions Kaplan-Meier survival analysis in the 600 patients according to e-intervention or not showed four-year survival curve and number at risk table.
Figure 2The consort diagram of study samples.
Figure 3The architecture of the information systems utilized in this study.
Figure 4The time regimens of the study groups classified by e-intervention.